Australian clinical-stage biotechnology company Vaxxas has expanded its global intellectual property portfolio to 42 patents, supporting its exclusive claim to manufacture and sell its proprietary vaccination technology, the HD-MAP, in the US, Europe, Asia and Australia. …
Vaxxas expands global IP portfolio for exclusive manufacture and sale of needle-free vaccination technology
November 27, 2024 Australian Biotech
Latest Video
New Stories
-
Biogen ANZ certified a 'Great Place to Work' for a fifth time
October 16, 2026 - - Latest News -
Tavneos to be withdrawn from Australia as CSL pulls vasculitis treatment
October 16, 2026 - - Latest News -
AI in HTA - survey reveals optimism and concern over a potential missed opportunity
October 16, 2026 - - Latest News -
England's chief scientific officer on the opportunity for Australia to get it right on genomics
October 15, 2026 - - Latest News -
The medicines gap costing Australian children time they can't get back
October 15, 2026 - - Latest News -
Brain cancer advocates return to Canberra 'to keep that ambition alive'
October 15, 2026 - - Latest News -
The effort to change an institution from within, works best when exit is possible
October 15, 2026 - - Latest News